Search results
Results from the WOW.Com Content Network
AOH1996 was created to target a post-translationally modified isoform of PCNA, termed caPCNA, which is preferentially found in cancer cells. PCNA is crucial in the body for DNA repair, but targeting it is difficult because of its role in healthy cells.
For premium support please call: 800-290-4726 more ways to reach us
Elacestrant was not McDonnell’s first attempt at bringing a breast cancer drug to market. In 1996, his lab developed a similar drug, etacstil, which was the first oral medication in this class ...
There has been ongoing controversy and litigation in Brazil with regard to its use as a cancer treatment without approval by the National Health Surveillance Agency.For years, Gilberto Chierice, a Chemistry Professor at the São Carlos campus of the University of São Paulo, used resources from a campus laboratory to unofficially manufacture, distribute, and promote the drug to cancer patients ...
Revumenib, sold under the brand name Revuforj, is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) rearrangements. [1] It is designed to disrupt the interaction between menin and KMT2A (also known as MLL), which plays a role in the pathogenesis of these leukemias. [ 2 ]
Scientists hope findings signal a major breakthrough in tackling leading cause of cancer deaths
A once-daily pill from drugmaker AstraZeneca cut deaths in half among a subset of early-stage lung cancer patients who had undergone surgery, according to new clinical trial results.
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. [ 1 ] [ 5 ] [ 7 ] It is an inhibitor of tropomyosin kinase receptors TrkA , TrkB , and TrkC . [ 8 ] [ 9 ] [ 10 ] It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.